Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study.

Among 2,186 U.S. adults with invasive cancer and laboratory-confirmed SARS-CoV-2 infection, we examined the association of COVID-19 treatments with 30-day all-cause mortality and factors associated with treatment. Logistic regression with multiple adjustments (e.g., comorbidities, cancer status, baseline COVID-19 severity) was performed. Hydroxychloroquine with any other drug was associated with increased mortality versus treatment with any COVID-19 treatment other than hydroxychloroquine or untreated controls; this association was not present with hydroxychloroquine alone. Remdesivir had numerically reduced mortality versus untreated controls that did not reach statistical significance. Baseline COVID-19 severity was strongly associated with receipt of any treatment. Black patients were approximately half as likely to receive remdesivir as white patients. Although observational studies can be limited by potential unmeasured confounding, our findings add to the emerging understanding of patterns of care for patients with cancer and COVID-19 and support evaluation of emerging treatments through inclusive prospective controlled trials. SIGNIFICANCE: Evaluating the potential role of COVID-19 treatments in patients with cancer in a large observational study, there was no statistically significant 30-day all-cause mortality benefit with hydroxychloroquine or high-dose corticosteroids alone or in combination; remdesivir showed potential benefit. Treatment receipt reflects clinical decision-making and suggests disparities in medication access.This article is highlighted in the In This Issue feature, p. 1426

Avaliação de dois simuladores para predição da lixiviação de sulfona de aldicarbe em um Latossolo Vermelho-Amarelo Evaluation of two simulators to predict the leaching of aldoxycarb in a red-yellow latossol

Este trabalho teve por objetivo o estudo da lixiviação de sulfona de aldicarbe em um Latossolo Vermelho-Amarelo, na região de Lavras, MG, para posterior comparação com os resultados obtidos pelos simuladores CALF e PESTLA. Os resultados mostraram alta lixiviação de sulfona de aldicarbe no solo em estudo. Aos 44 dias após a aplicação do inseticida e com uma lâmina de água acumulada de 241,4 mm, a quantidade média de sulfona de aldicarbe remanescente nas colunas de solo de 45 cm de profundidade foi equivalente a 17,92% (±5,88) da dose aplicada, enquanto os simuladores CALF e PESTLA estimaram 20,52% e 37,82%, respectivamente. O simulador CALF gerou melhores estimativas da quantidade média de sulfona de aldicarbe no perfil do solo nas diferentes datas de amostragem, enquanto o simulador PESTLA gerou melhores estimativas da distribuição do inseticida ao longo do perfil do solo, nas diferentes datas de amostragem.<br>This work was carried out to study the leaching of aldoxycarb in a Red Yellow Latossol in Lavras, Minas Gerais State, Brazil, and to compare the observed results with those obtained by the simulators CALF and PESTLA. The results showed a high leaching of aldoxycarb in the soil. After 44 days of the insecticide application and with 241.4 mm of accumulated water applied in each column, the remained quantity of aldoxycarb in the soil columns (45 cm long) was 17.92% (±5.88) of the initial applied rate. However, the simulators CALF and PESTLA predicted 20.52% and 37.82%, respectively. CALF simulator gave better predictions of the overall mean residue concentrations of aldoxycarb, and PESTLA simulator gave better prediction of residues distribution